Nozinan (Levomepromazine Maleate)

Levomepromazine, the active ingredient in Nozinan, is a phenothiazine presented as a 25 mg tablet for oral use. It is employed in the management of severe agitation, psychotic disorders, and nausea in adult patients. GNH USA supplies Nozinan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Nozinan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levomepromazine is a phenothiazine antipsychotic that acts on dopaminergic and serotonergic pathways to control several psychiatric and supportive care conditions.

- Schizophrenia: helps reduce hallucinations, delusions and thought disorder. - Severe agitation or psychomotor excitement: calms patients who are acutely disturbed. - Nausea and vomiting associated with cancer therapy: provides anti‑emetic relief when other agents are insufficient. - Palliative‑care symptom control: eases distressing symptoms such as anxiety and pain‑related insomnia.

Levomepromazine may cause a range of adverse reactions, from mild to potentially serious.

Common Side Effects: - Drowsiness - Dry mouth - Constipation - Orthostatic hypotension - Blurred vision - Weight gain

Serious or Rare Side Effects: - Extrapyramidal symptoms (e.g., dystonia, akathisia) - Neuroleptic malignant syndrome - Severe hypotension - Cardiac arrhythmias - Agranulocytosis - Hepatotoxic ​​  

Levomepromazine requires  

-    t   t  ewline   ewline   lank \